Nimotuzumab with chemoradiotherapy

COMBINATION_PRODUCT2 trials

Sponsors

Cancer Institute and Hospital, Chinese Academy of Medical Sciences

Conditions

ChemoradiotherapyChemotherapyEsophageal CancerImmunotherapyNimotuzumab

Phase 2

Nimotuzumab Concurrent With Chemoradiotherapy for Patients With Unresectable Esophageal Squamous Cell Carcinoma

RecruitingNCT06410651

Cancer Institute and Hospital, Chinese Academy of Medical SciencesChemoradiotherapy, Chemotherapy, Esophageal Cancer +2

Start: 2023-03-01End: 2026-12-31Target: 53Updated: 2024-05-13

Nimotuzumab Concurrent With Chemoradiotherapy for Esophageal Cancer Patients

RecruitingNCT06429839

Cancer Institute and Hospital, Chinese Academy of Medical SciencesChemoradiotherapy, Chemotherapy, Esophageal Cancer +2

Start: 2023-03-01End: 2026-12-31Target: 55Updated: 2024-05-28